Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Lifted by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC grew its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 6.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 3,182 shares of the biopharmaceutical company’s stock after buying an additional 192 shares during the period. Pallas Capital Advisors LLC’s holdings in Intra-Cellular Therapies were worth $266,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of ITCI. True Wealth Design LLC acquired a new position in shares of Intra-Cellular Therapies during the third quarter valued at approximately $32,000. GAMMA Investing LLC increased its stake in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 240 shares during the period. Capital Performance Advisors LLP acquired a new position in shares of Intra-Cellular Therapies during the third quarter valued at approximately $74,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Intra-Cellular Therapies during the third quarter valued at approximately $97,000. Finally, Quarry LP increased its stake in shares of Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after acquiring an additional 1,300 shares during the period. Institutional investors own 92.33% of the company’s stock.

Wall Street Analyst Weigh In

ITCI has been the topic of a number of research analyst reports. Royal Bank of Canada raised their price objective on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Needham & Company LLC restated a “hold” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a research report on Monday. Morgan Stanley lifted their price target on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Finally, Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday. Six equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Intra-Cellular Therapies currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.31.

Intra-Cellular Therapies Stock Performance

Intra-Cellular Therapies stock opened at $126.71 on Thursday. The company has a 50 day moving average price of $87.89 and a 200 day moving average price of $80.00. Intra-Cellular Therapies, Inc. has a 52 week low of $62.78 and a 52 week high of $128.00. The firm has a market capitalization of $13.43 billion, a price-to-earnings ratio of -145.64 and a beta of 0.70.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The company had revenue of $175.40 million for the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company’s quarterly revenue was up 39.0% on a year-over-year basis. During the same period last year, the business earned ($0.25) EPS. Equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Buying and Selling at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, President Michael Halstead sold 22,869 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. Company insiders own 2.60% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.